A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
Completed · Phase 2 · Has a placebo group
Conditions studied: Plaque Psoriasis
In brief
The purpose of the study is to evaluate the efficacy of an oral tablet formulation of JNJ-77242113 compared with placebo in participants with moderate-to-severe plaque psoriasis.
Key facts
- Study ID
- NCT05357755
- Run by
- Janssen Research & Development, LLC
- People needed
- 90
- Starts
- 2022-06-13
- Expected to finish
- 2023-04-10
- Last updated by the study team
- 2026-05-05
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participant has a diagnosis of plaque psoriasis, with or without psoriatic arthritis, for at least 26 weeks prior to the first administration of study intervention
- Participant has a total Body Surface Area (BSA) greater than or equal to (>=) 10 percentage (%) at screening and baseline
- Participant has a total Psoriasis Area and Severity Index (PASI) >= 12 at screening and baseline
- Participant has a total Investigator's Global Assessment (IGA) >= 3 at screening and baseline
- Participant be a candidate for phototherapy or systemic treatment for plaque psoriasis
You may not qualify if…
- Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
- Participant has current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- Participant have previously received any other therapeutic agent directly targeted to interleukin 23 (including but not limited to guselkumab, tildrakizumab, or risankizumab)
- Participant has received any therapeutic agent directly targeted to interleukin 17 (IL-17), interleukin 17 receptor (IL-17R) or interleukin 12/23 (IL-12/23) (including but not limited to secukinumab, ixekizumab, brodalumab, or ustekinumab) or has received biological therapy targeting tumor necrosis factor (TNF) (including, but not limited to adalimumab, infliximab, or etanercept) within 12 weeks or 5 half-lives, whichever is longer, of the first administration of study intervention
- Participant has received proton pump inhibitors (including but not limited to omeprazole, esomeprazole, lansoprazole, rabeprazole, pantoprazole, dexlansoprazole, or zegerid) within 1 week of first administration of study intervention
Where it is running
- Dermatology Research Institute Inc — Calgary, Alberta, Canada
- Stoll Dermatology — Beverly Hills, California, United States
- Northshore University Healthsystem — Skokie, Illinois, United States
- Epiphany Dermatology of Kansas, LLC — Overland Park, Kansas, United States
- Dermatology Specialists — Louisville, Kentucky, United States
- Lawrence J Green MD LLC — Rockville, Maryland, United States
- ActivMed Practices and Research — Beverly, Massachusetts, United States
- ActivMed Practices and Research — Portsmouth, New Hampshire, United States
- Windsor Dermatology, PC — East Windsor, New Jersey, United States
- Unity Clinical Research — Oklahoma City, Oklahoma, United States
- The Pennsylvania Centre for Dermatology, LLC — Exton, Pennsylvania, United States
- Health Concepts — Rapid City, South Dakota, United States
- Arlington Center for Dermatology — Arlington, Texas, United States
- The Guenther Dermatology Research Centre — London, Ontario, Canada
- Lynderm Research Inc. — Markham, Ontario, Canada
- DermEdge Research — Mississauga, Ontario, Canada
- Toronto Research Centre — Toronto, Ontario, Canada
- CHRU Brest - Hopital Morvan — Brest, France
- CHU de Grenoble Hopital Albert Michallon — La Tronche, France
- CHU de Nice Hopital de l Archet — Nice, France
- Polyclinique de Courlancy — Reims, France
- Hautarztpraxis — Bramsche, Germany
- Universitatsklinikum Carl Gustav Carus Dresden — Dresden, Germany
- Privatpraxis Dr. Hilton & Partner — Düsseldorf, Germany
- Universitatsklinikum Frankfurt — Frankfurt am Main, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.